X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SANOFI INDIA AJANTA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 20.4 40.3 50.7% View Chart
P/BV x 4.8 8.7 55.2% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 AJANTA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
SANOFI INDIA
Dec-16
AJANTA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,8184,560 39.9%   
Low Rs1,1064,400 25.1%   
Sales per share (Unadj.) Rs239.51,028.5 23.3%  
Earnings per share (Unadj.) Rs52.8129.0 40.9%  
Cash flow per share (Unadj.) Rs59.5186.0 32.0%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs230.0753.6 30.5%  
Shares outstanding (eoy) m88.7723.03 385.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.14.4 140.2%   
Avg P/E ratio x27.734.7 79.7%  
P/CF ratio (eoy) x24.624.1 102.0%  
Price / Book Value ratio x6.45.9 106.9%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m129,782103,174 125.8%   
No. of employees `0006.83.6 187.6%   
Total wages/salary Rs m3,7653,592 104.8%   
Avg. sales/employee Rs Th3,128.46,537.7 47.9%   
Avg. wages/employee Rs Th554.0991.4 55.9%   
Avg. net profit/employee Rs Th689.7819.8 84.1%   
INCOME DATA
Net Sales Rs m21,25823,686 89.7%  
Other income Rs m242708 34.1%   
Total revenues Rs m21,49924,394 88.1%   
Gross profit Rs m6,5845,281 124.7%  
Depreciation Rs m5961,313 45.4%   
Interest Rs m415 27.3%   
Profit before tax Rs m6,2264,661 133.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,691 91.0%   
Profit after tax Rs m4,6862,970 157.8%  
Gross profit margin %31.022.3 138.9%  
Effective tax rate %24.736.3 68.1%   
Net profit margin %22.012.5 175.8%  
BALANCE SHEET DATA
Current assets Rs m12,23615,673 78.1%   
Current liabilities Rs m3,4616,678 51.8%   
Net working cap to sales %41.338.0 108.7%  
Current ratio x3.52.3 150.7%  
Inventory Days Days6076 79.2%  
Debtors Days Days8422 378.6%  
Net fixed assets Rs m11,1408,098 137.6%   
Share capital Rs m177230 76.8%   
"Free" reserves Rs m20,23717,088 118.4%   
Net worth Rs m20,41417,356 117.6%   
Long term debt Rs m100-   
Total assets Rs m24,48625,400 96.4%  
Interest coverage x1,519.4311.7 487.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 93.1%   
Return on assets %19.211.8 163.0%  
Return on equity %23.017.1 134.2%  
Return on capital %30.526.9 113.2%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m11,6677,145 163.3%   
Fx outflow Rs m1,6166,846 23.6%   
Net fx Rs m10,052299 3,361.8%   
CASH FLOW
From Operations Rs m2,8543,226 88.5%  
From Investments Rs m-2,604-1,555 167.5%  
From Financial Activity Rs m-2-1,818 0.1%  
Net Cashflow Rs m248-147 -168.8%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 1.6 14.4 10.8%  
FIIs % 7.6 14.6 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 15,184 138.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS